Pharmaceutical

Reduce Wasteful Work-arounds

Pharmaceutical synthesis requires large-scale ultra-pure synthesis of simple and complex molecules. Currently, the industry faces the following issues:

• High Production costs, directly proportional to the need for cleaner end-products and elaborate work-arounds
• Reduction chemistries within pharmaceutical synthesis use difficult processing conditions and produce unwanted by-products, which in turn, leads to the need for significant purification and/or lower yields of valuable product

Pharmaceutical development is in need of process materials that provide clean chemistry with stoichiometric molecular combination with simple and safe process steps as well as the potential to be brought from single batch processes into continuous flow product generation.

SiGNa’s process development services offer an innovative service platform which bundles its stabilized reactive metal products, its know-how, and unparalleled services for the pharmaceutical industry. Our customers benefit from the effective integration of our company-wide knowledge-base.

Building from our growing product portfolio and outstanding services in the areas of synthesis and formulation, SiGNa is a highly desired R&D partner in the pharmaceutical industry.